Weekly Investment Analysts’ Ratings Changes for Deciphera Pharmaceuticals (DCPH)

Several analysts have recently updated their ratings and price targets for Deciphera Pharmaceuticals (NASDAQ: DCPH):

  • 11/21/2019 – Deciphera Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 11/13/2019 – Deciphera Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 11/7/2019 – Deciphera Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “
  • 11/5/2019 – Deciphera Pharmaceuticals had its price target raised by analysts at JMP Securities from $45.00 to $54.00. They now have a “market outperform” rating on the stock.
  • 11/5/2019 – Deciphera Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/29/2019 – Deciphera Pharmaceuticals was upgraded by analysts at Svb Leerink Llc from an “underperform” rating to a “market perform” rating. They now have a $34.00 price target on the stock, up previously from $29.00.
  • 10/29/2019 – Deciphera Pharmaceuticals was upgraded by analysts at Leerink Swann from an “underperform” rating to a “market perform” rating.
  • 10/29/2019 – Deciphera Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/22/2019 – Deciphera Pharmaceuticals is now covered by analysts at JMP Securities. They set an “outperform” rating on the stock.
  • 10/19/2019 – Deciphera Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 10/4/2019 – Deciphera Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $40.00 price target on the stock. According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “
  • 10/3/2019 – Deciphera Pharmaceuticals is now covered by analysts at HC Wainwright. They set a “buy” rating and a $60.00 price target on the stock.
  • 9/30/2019 – Deciphera Pharmaceuticals was given a new $55.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 9/30/2019 – Deciphera Pharmaceuticals is now covered by analysts at Jefferies Financial Group Inc. They set a “buy” rating and a $47.00 price target on the stock.
  • 9/27/2019 – Deciphera Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

DCPH stock traded down $0.20 during midday trading on Thursday, hitting $47.80. 925,500 shares of the company’s stock were exchanged, compared to its average volume of 410,227. Deciphera Pharmaceuticals Inc has a 12-month low of $19.69 and a 12-month high of $49.97. The firm has a 50 day moving average price of $39.78 and a 200-day moving average price of $30.27. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of -16.95 and a beta of 1.96.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Monday, November 4th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($0.09). On average, sell-side analysts forecast that Deciphera Pharmaceuticals Inc will post -4.25 earnings per share for the current fiscal year.

In other news, CFO Thomas Patrick Kelly sold 3,750 shares of the company’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $44.34, for a total value of $166,275.00. Also, insider Daniel C. Martin sold 3,000 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $35.56, for a total value of $106,680.00. In the last 90 days, insiders sold 255,747 shares of company stock valued at $11,681,021. Insiders own 7.02% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC lifted its holdings in shares of Deciphera Pharmaceuticals by 2.1% during the second quarter. Janus Henderson Group PLC now owns 675,707 shares of the company’s stock valued at $15,237,000 after purchasing an additional 14,028 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Deciphera Pharmaceuticals by 120.9% during the second quarter. CIBC Asset Management Inc now owns 91,142 shares of the company’s stock valued at $2,055,000 after purchasing an additional 49,884 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Deciphera Pharmaceuticals by 325.2% during the second quarter. Wells Fargo & Company MN now owns 65,123 shares of the company’s stock valued at $1,468,000 after purchasing an additional 49,806 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Deciphera Pharmaceuticals by 89.2% during the second quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock valued at $95,000 after purchasing an additional 1,913 shares during the last quarter. Finally, Alps Advisors Inc. purchased a new stake in shares of Deciphera Pharmaceuticals during the second quarter valued at $1,802,000. Institutional investors and hedge funds own 46.68% of the company’s stock.

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Article: How is diluted EPS different from basic EPS?

Receive News & Ratings for Deciphera Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.